Meropenem
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Meropenem: From Serious Bacterial Infections to Bacterial Arthritis
One-Sentence Summary
Meropenem is a broad-spectrum carbapenem antibiotic administered intravenously for severe bacterial infections including intra-abdominal infections, hospital-acquired pneumonia, bloodstream infections, and meningitis. The TxGNN model predicts it may be effective for Bacterial Arthritis, with 1 clinical trial and 20 publications currently supporting this direction. Evidence is primarily observational and case-based (Level L3), indicating this is a biologically plausible use that warrants further prospective investigation rather than immediate clinical adoption.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Serious bacterial infections (intra-abdominal, nosocomial pneumonia, septicaemia, meningitis) |
| Predicted New Indication | Bacterial Arthritis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Meropenem is a carbapenem-class β-lactam antibiotic that exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall peptidoglycan synthesis. Its broad-spectrum activity covers Gram-negative pathogens including Pseudomonas aeruginosa, ESBL-producing Enterobacteriaceae, Acinetobacter baumannii, Campylobacter spp., and anaerobes. This same cell-wall inhibition mechanism mechanistically applies to the Gram-negative pathogens most commonly responsible for bacterial arthritis in immunocompromised or healthcare-associated settings.
Bacterial (septic) arthritis caused by multidrug-resistant Gram-negative organisms — including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Burkholderia pseudomallei (melioidosis) — is precisely the scenario where first-line agents (penicillins, fluoroquinolones) frequently fail. Retrospective cohort data from melioidosis-endemic regions (South India, Southeast Asia) consistently show that meropenem is the only reliably active agent against Burkholderia pseudomallei in osteoarticular disease, with 100% susceptibility reported across multiple study cohorts. Synovial fluid penetration of meropenem is estimated at approximately 50–60% of concurrent serum concentrations — sufficient to exceed MIC breakpoints for most susceptible Gram-negative pathogens in the joint space.
The TxGNN model’s prediction therefore aligns with real-world prescribing practice: meropenem is already used off-label for Gram-negative septic arthritis in clinical settings, particularly in prosthetic joint infections with MDR organisms, and as a standard intensification therapy for melioidosis-associated osteoarticular disease. The gap is not biological plausibility, but the absence of prospective controlled trials specifically targeting this indication.
Clinical Trial Evidence
Only one trial was retrieved; it is only tangentially related to this indication and does not evaluate meropenem directly for bacterial arthritis.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01371656 | Phase 3 | Completed | 624 | Levofloxacin prophylaxis for bacteremia prevention in pediatric acute leukemia and HSCT patients; meropenem is not the study drug and bacterial arthritis is not the study endpoint — minimal relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39489417 | 2024 | Retrospective Review | Indian J Med Microbiol | 22 cases of culture-confirmed musculoskeletal melioidosis including septic arthritis; all isolates were susceptible to meropenem, supporting its role as standard-of-care in osteoarticular melioidosis |
| 35146367 | 2021 | Retrospective Cohort | Le Infezioni in Medicina | Osteoarticular melioidosis cohort study; characterizes fever, bone/joint involvement, and treatment outcomes; meropenem used as intensification therapy |
| 37713001 | 2024 | Antibiogram Study | Eur J Orthop Surg Traumatol | Antibiogram of bacterial isolates from orthopaedic infections (including septic arthritis, osteomyelitis, prosthetic joint infections) in a developing-world setting; identifies optimal empiric antibiotic strategies including carbapenem-class agents |
| 39193962 | 2024 | Epidemiological Study | Clinical Laboratory | Pathogen distribution and antimicrobial resistance in bone and joint infections in children under 4 years old; context for empiric antibiotic selection |
| 33857030 | 2021 | In vitro / Lab Study | J Bone Joint Surg Am | Thermal stability and elution kinetics of meropenem from PMMA bone cement; establishes that meropenem retains activity after exothermic polymerisation — supports local delivery in orthopaedic infections |
| 31319190 | 2019 | Animal Study | Int J Antimicrobial Agents | Colistin-impregnated cement spacer combined with systemic meropenem evaluated in a rabbit model of carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection; meropenem is used as the backbone systemic agent |
| 38134096 | 2023 | Case Report | Medicine | Campylobacter fetus-induced primary psoas abscess in a patient with gouty arthritis; meropenem-based regimen described as treatment backbone for Gram-negative joint/soft-tissue infection |
| 38139869 | 2023 | Case Report | Pharmaceuticals | Septic arthritis of the native hip joint caused by Bacillus pumilus and Paenibacillus barengoltzii in an immunocompetent adult; highlights challenges of unusual-pathogen bacterial arthritis and antibiotic choice |
| 36804370 | 2023 | Review | Int J Antimicrobial Agents | Off-label versus guideline-recommended use of conventional and novel antibiotics for MDR bacterial infections including Gram-negative organisms associated with joint infections |
| 2808217 | 1989 | In vitro Study | J Antimicrobial Chemother | Foundational bacteriostatic and bactericidal in vitro activity study of meropenem; demonstrates meropenem is bactericidal for Pseudomonas spp. and staphylococci, with MBCs only 2-fold above MIC |
India Market Information
No registered products for Meropenem were identified in the India regulatory database within this evidence pack. No authorisation table can be generated.
Safety Considerations
Drug Interactions (14 interactions identified from DDInter database):
Major interactions (exercise caution or avoid co-administration):
- Bupropion — carbapenems, including meropenem, are well-documented to significantly reduce serum valproic acid levels (by up to 60–90%); concomitant bupropion further lowers seizure threshold, creating substantial seizure risk
- Iohexol (iodinated contrast medium) — major interaction; may potentiate nephrotoxicity or adverse haemodynamic effects
- Iopamidol (iodinated contrast medium) — major interaction; same class concern as iohexol
Moderate interactions (monitor closely):
- Mycophenolic acid — meropenem reduces mycophenolate plasma levels; risk of under-immunosuppression in transplant patients
- Ethinylestradiol — potential reduction in oral contraceptive efficacy
- Pemetrexed — carbapenems may reduce pemetrexed renal clearance, increasing toxicity risk
- Teriflunomide, Alpelisib, Encorafenib — pharmacokinetic interactions requiring monitoring
- Picosulfuric acid, Polyethylene glycol with electrolytes, Sodium sulfate, Nitisinone, Lindane — moderate interactions, clinical significance context-dependent
Please refer to the package insert for complete warnings and contraindications, which were not available in this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: While Meropenem has robust biological plausibility for bacterial arthritis caused by MDR Gram-negative organisms — particularly in melioidosis and prosthetic joint infection settings — evidence is limited to retrospective studies, case reports, and in vitro data (Level L3). There are no prospective Phase 2/3 RCTs evaluating meropenem specifically for the bacterial arthritis indication, and current use is based on susceptibility profiles rather than controlled clinical evidence.
To proceed, the following is needed:
- Prospective observational or controlled trial data evaluating meropenem efficacy specifically for MDR Gram-negative septic arthritis
- Synovial fluid pharmacokinetic studies (in vivo joint penetration data) to confirm adequate exposure at the site of infection
- MOA data from DrugBank to strengthen the mechanistic justification section
- India/CDSCO regulatory filing and approval status clarification (Meropenem is available in many global markets; the zero-registration result in this evidence pack should be verified against current CDSCO databases)
- Complete safety data from the package insert, including warnings, contraindications, and dosing in renal impairment
- Antimicrobial stewardship (AMS) criteria and protocol for appropriate carbapenem use in joint infections, to distinguish this indication from first-line antibiotic use cases
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.